Search InvestCenter

Recent Quotes

My Watchlist

Top Indices

Latest News about SNY

Recent news which mentions SNY

< Previous 1 2 3 4 5 6 7 8 9

...

Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast

October 25, 2024

Sanofi's Earnings Outlook

October 24, 2024

Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business

October 21, 2024

This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?

October 21, 2024

European Medicines Agency's Panel Supports Approval Of Novartis' Kisqali In Patients With Early-Breast Cancer

October 18, 2024

France's PAI Partners Ups Bid for Sanofi's Consumer Health Division As French Government Hints Possible Regulatory Block

October 18, 2024

Sanofi Might Face Political Hurdles In $16B Consumer Pharma Unit Sale To US Private Equity CD&R

October 15, 2024

World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice

October 11, 2024

Denali Therapeutics Stock Is Sliding After The Bell: Here's Why

October 10, 2024

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields

October 07, 2024

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains

October 07, 2024

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report

October 04, 2024

Sanofi Sells Global Rights To Rare Autoimmume Drug Enjaymo For $825M Upfront To Italian Firm Recordati

October 04, 2024

Novo Nordisk/AstraZeneca's Manufacturing Partner Thermo Fisher Questioned Over Manufacturing Lapses

October 04, 2024

US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next

October 01, 2024

FDA Approves Regeneron/Sanofi's Blockbuster Dupixent For Smoker's Lung Disease

September 27, 2024

Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs

September 25, 2024

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

September 25, 2024

Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff

September 25, 2024

Sanofi Injects $27M In Neurology Drug Developer Ventyx Biosciences

September 23, 2024

Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval

September 23, 2024

US Federal Trade Commission Sues CVS Health, Cigna, UnitedHealth's Pharmacy Benefit Managers For Inflating Insulin Prices

September 20, 2024

Sanofi's Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows

September 20, 2024

Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability Progression For Up To Six Years

September 18, 2024

Should You Buy Novavax Stock After This Regulatory Win?

September 13, 2024

Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease

September 11, 2024

FDA Battles Backlog of Drug Factory Inspections Since COVID-19

September 06, 2024

Why Sanofi Stock Was Robustly Healthy Today

September 03, 2024

Sanofi Still Bets On Multiple Sclerosis Med Tolebrutinib Despite The Investigational Drug Fell Short In 2 Of 3 Phase 3 Trials

September 03, 2024

European Stocks Little Moved On Labor Day, German DAX Mark Record Close, Natural Gas Futures Rise: What's Driving Markets Monday?

September 02, 2024

< Previous 1 2 3 4 5 6 7 8 9

...

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

© 2025 FinancialContent. All rights reserved.